LORTAB ELIXIR CII
Generic Name and Formulations:
Hydrocodone bitartrate 10mg, acetaminophen 300mg; per 15mL; tropical fruit punch flavor; contains alcohol 7%.
Indications for LORTAB ELIXIR:
Moderate to moderately severe pain.
11.25mL every 4–6hrs as needed; max 67.5mL/day.
<2yrs: not recommended. Give every 4–6hrs as needed; max 6 doses/day. 2–3yrs (12–15kg): 2.8mL; max: 16.8mL/day. 4–6yrs (16–22kg): 3.75mL; max: 22.5mL/day. 7–9yrs (23–31kg): 5.6mL; max: 33.6mL/day. 10–13yrs (32–45kg): 7.5mL; max: 45mL/day. ≥14yrs (≥46kg): 11.25mL; max: 67.5mL.
Head injury. Increased intracranial pressure. Acute abdomen. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Drug abusers. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiation with alcohol, CNS depressants, MAOIs, tricyclic antidepressants, anticholinergics.
Opioid + analgesic.
Dizziness, CNS depression, respiratory depression, GI upset, constipation, urinary retention; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation